HomepageP8A • SGX
add
Cordlife Group Ltd
Vorige slotkoers
$ 0,27
Dag-range
$ 0,24 - $ 0,27
Jaar-range
$ 0,12 - $ 0,33
Beurswaarde
63,06 mln. SGD
Gem. volume
97,50K
Koers/winst
-
Dividendrendement
-
Primaire beurs
SGX
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (SGD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 9,23 mln. | -32,68% |
Bedrijfskosten | 9,20 mln. | -4,76% |
Netto inkomsten | -3,26 mln. | -602,85% |
Netto winstmarge | -35,37 | -847,78% |
Winst per aandeel | — | — |
EBITDA | -3,28 mln. | -1.210,17% |
Effectief belastingtarief | -19,78% | — |
Balans
Totale activa
Totale passiva
| (SGD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 61,14 mln. | -7,40% |
Totale activa | 217,14 mln. | -4,95% |
Totale passiva | 98,68 mln. | 6,33% |
Totaal aandelenvermogen | 118,46 mln. | — |
Uitstaande aandelen | 256,31 mln. | — |
Koers-boekwaardeverhouding | 0,59 | — |
Rendement op activa | -4,75% | — |
Rendement op kapitaal | -8,54% | — |
Kasstroom
Nettomutatie in liquide middelen
| (SGD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -3,26 mln. | -602,85% |
Operationele kasstroom | -2,70 mln. | -257,73% |
Kasstroom uit beleggingen | -3,86 mln. | -850,10% |
Kasstroom uit financiering | 3,68 mln. | 881,72% |
Nettomutatie in liquide middelen | -2,96 mln. | -287,36% |
Vrije kasstroom | -2,63 mln. | -1.712,17% |
Over
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
CEO
Opgericht
2 mei 2001
Website
Werknemers
111
